Drug intelligence / Profile preview

Colchicine, Diclofenac, and Sulfasalazine (Combination)

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

This appears to be a combination of three separate medications rather than a single formulated combination drug. Each component has its own distinct properties and uses. ## Colchicine Colchicine is indicated for the prophylaxis and treatment of gout flares, Familial Mediterranean fever (FMF), and to reduce the risk of cardiovascular events in patients with established atherosclerotic disease or multiple risk factors for cardiovascular disease[4]. It's also used off-label for conditions like Behcet's syndrome and pericarditis[4]. ## Diclofenac Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. It has a moderate drug interaction with sulfasalazine, where diclofenac may decrease the therapeutic efficacy of sulfasalazine[1][3]. ## Sulfasalazine Sulfasalazine is indicated for treating mild to moderate ulcerative colitis, prolonging remission between acute attacks, and as an adjunct therapy in severe ulcerative colitis[1]. The delayed-release formulation is also indicated for rheumatoid arthritis in certain pediatric patients[1]. It's sometimes used off-label for Crohn's disease, distal ulcerative colitis, and proctitis[1]. ## Drug Interactions There are notable interactions between these medications: - Diclofenac can decrease the therapeutic efficacy of sulfasalazine when used in combination[1][3]. - Sulfasalazine has 271 known drug interactions in total, with 46 major, 216 moderate, and 9 minor interactions[2]. - Patients with certain conditions may need to use these medications with caution, as sulfasalazine has 12 disease interactions including colitis, liver disease, renal dysfunction, and folate deficiency[2]. The combination of these three medications would need careful monitoring due to their individual side effect profiles and potential interactions. This is not a standard fixed-dose combination product but rather three separate medications that might be prescribed together for specific clinical situations.

Other names
Sulphasalazine
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on Colchicine, Diclofenac, and Sulfasalazine (Combination).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colchicine, Diclofenac, and Sulfasalazine (Combination).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call